Cargando…

The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia

The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor signaling pathways i...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Marques, Miguel A. T., Sidler, Corinne, Mueller, Beatrice U., Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025168/
https://www.ncbi.nlm.nih.gov/pubmed/29857559
http://dx.doi.org/10.3390/cancers10060170
_version_ 1783336222600462336
author Seipel, Katja
Marques, Miguel A. T.
Sidler, Corinne
Mueller, Beatrice U.
Pabst, Thomas
author_facet Seipel, Katja
Marques, Miguel A. T.
Sidler, Corinne
Mueller, Beatrice U.
Pabst, Thomas
author_sort Seipel, Katja
collection PubMed
description The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor signaling pathways including the mitogen-activated kinase (MAPK) cascade (RAS-RAF-MEK-ERK) are highly active in AML cells. Consequently, the combined administration of MDM2 and MEK inhibitors may present a promising anti-leukemic treatment strategy. Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death. AML cell lines and blast cells comprised all major AML subtypes based on the mutational status of TP53, FLT3 and NPM1 genes. We observed a considerably varying anti-leukemic efficacy of idasanutlin and cobimetinib. AML cells with high sensitivity to the single compounds as well as to the combined treatment emerged with normal karyotype, wild-type TP53 and elevated FLT3 and MDM2 protein levels. Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin. FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML.
format Online
Article
Text
id pubmed-6025168
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60251682018-07-09 The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia Seipel, Katja Marques, Miguel A. T. Sidler, Corinne Mueller, Beatrice U. Pabst, Thomas Cancers (Basel) Article The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML). Moreover, fms like tyrosine kinase 3 (FLT3) growth factor signaling pathways including the mitogen-activated kinase (MAPK) cascade (RAS-RAF-MEK-ERK) are highly active in AML cells. Consequently, the combined administration of MDM2 and MEK inhibitors may present a promising anti-leukemic treatment strategy. Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death. AML cell lines and blast cells comprised all major AML subtypes based on the mutational status of TP53, FLT3 and NPM1 genes. We observed a considerably varying anti-leukemic efficacy of idasanutlin and cobimetinib. AML cells with high sensitivity to the single compounds as well as to the combined treatment emerged with normal karyotype, wild-type TP53 and elevated FLT3 and MDM2 protein levels. Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin. FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML. MDPI 2018-05-31 /pmc/articles/PMC6025168/ /pubmed/29857559 http://dx.doi.org/10.3390/cancers10060170 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seipel, Katja
Marques, Miguel A. T.
Sidler, Corinne
Mueller, Beatrice U.
Pabst, Thomas
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title_full The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title_fullStr The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title_full_unstemmed The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title_short The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
title_sort cellular p53 inhibitor mdm2 and the growth factor receptor flt3 as biomarkers for treatment responses to the mdm2-inhibitor idasanutlin and the mek1 inhibitor cobimetinib in acute myeloid leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025168/
https://www.ncbi.nlm.nih.gov/pubmed/29857559
http://dx.doi.org/10.3390/cancers10060170
work_keys_str_mv AT seipelkatja thecellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT marquesmiguelat thecellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT sidlercorinne thecellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT muellerbeatriceu thecellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT pabstthomas thecellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT seipelkatja cellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT marquesmiguelat cellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT sidlercorinne cellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT muellerbeatriceu cellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia
AT pabstthomas cellularp53inhibitormdm2andthegrowthfactorreceptorflt3asbiomarkersfortreatmentresponsestothemdm2inhibitoridasanutlinandthemek1inhibitorcobimetinibinacutemyeloidleukemia